- Home
- BWMN vs ERAS Comparison
BWMN vs ERAS Comparison
Compare BWMN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWMN
- ERAS
- Stock Information
- Founded
- BWMN 1995
- ERAS 2018
- Country
- BWMN United States
- ERAS United States
- Employees
- BWMN N/A
- ERAS N/A
- Industry
- BWMN Military/Government/Technical
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- BWMN Consumer Discretionary
- ERAS Health Care
- Exchange
- BWMN Nasdaq
- ERAS Nasdaq
- Market Cap
- BWMN 368.1M
- ERAS 432.6M
- IPO Year
- BWMN 2021
- ERAS 2021
- Fundamental
- Price
- BWMN $21.93
- ERAS $1.26
- Analyst Decision
- BWMN Strong Buy
- ERAS Strong Buy
- Analyst Count
- BWMN 3
- ERAS 6
- Target Price
- BWMN $33.83
- ERAS $4.83
- AVG Volume (30 Days)
- BWMN 152.0K
- ERAS 1.8M
- Earning Date
- BWMN 03-11-2025
- ERAS 05-07-2025
- Dividend Yield
- BWMN N/A
- ERAS N/A
- EPS Growth
- BWMN N/A
- ERAS N/A
- EPS
- BWMN 0.17
- ERAS N/A
- Revenue
- BWMN $426,564,000.00
- ERAS N/A
- Revenue This Year
- BWMN $14.23
- ERAS N/A
- Revenue Next Year
- BWMN $7.85
- ERAS N/A
- P/E Ratio
- BWMN $127.53
- ERAS N/A
- Revenue Growth
- BWMN 23.19
- ERAS N/A
- 52 Week Low
- BWMN $17.90
- ERAS $1.04
- 52 Week High
- BWMN $36.65
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- BWMN 45.52
- ERAS 36.09
- Support Level
- BWMN $21.18
- ERAS $1.40
- Resistance Level
- BWMN $25.00
- ERAS $1.61
- Average True Range (ATR)
- BWMN 1.39
- ERAS 0.12
- MACD
- BWMN -0.13
- ERAS -0.01
- Stochastic Oscillator
- BWMN 19.63
- ERAS 38.60
About BWMN Bowman Consulting Group Ltd.
Bowman Consulting Group Ltd is a professional services firm delivering engineering solutions to customers who own, develop, and maintain the built environment. It provides planning, engineering, construction management, commissioning, environmental consulting, geospatial, survey, land procurement, and other technical services to customers operating in a diverse set of end markets. Its services include Civil & Site Engineering, Transportation Engineering, MEP Engineering, Commissioning & Energy Efficiency, Energy Services, Water/Wastewater, Fire Protection, Construction Management, Survey/Geospatial, Environmental Consulting, Structural Engineering, Land Procurement & Right-of-Way, Landscape, and Architecture/Planning.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.